Botulinum neurotoxin for the treatment of movement disorders.

Aust J Gen Pract

MD (Med), DM (Neuro), FRACP, Neurologist, Staff Specialist, Canberra Hospital.

Published: September 2018

Background: Botulinum neurotoxin (BoNT) is an exotoxin that causes neuromuscular weakness. BoNT serotypes A and B have been used for decades for the safe and effective treatment of various movement disorders, including some forms of focal dystonia. These conditions, such as cervical dystonia, hemifacial spasm, blepharospasm and spasmodic dysphonia, can have a substantial impact on patients' quality of life, but are often under-recognised.

Objective: The aim of this article is to describe the usefulness of BoNT for the treatment of movement disorders, including a description of its mechanism of action, mode of administration, indications and evidence of benefit.

Discussion: General practitioners have a vital role in the identification of patients with potentially treatable movement disorders such as cervical dystonia. Treatment with BoNT can improve patients' function, reduce pain and improve workforce participation. Patients require ongoing periodic injections by a trained neurologist to obtain long-term benefits with minimal side effects.

Download full-text PDF

Source
http://dx.doi.org/10.31128/AJGP-05-18-4589DOI Listing

Publication Analysis

Top Keywords

movement disorders
16
treatment movement
12
botulinum neurotoxin
8
disorders including
8
cervical dystonia
8
treatment
4
neurotoxin treatment
4
movement
4
disorders
4
disorders background
4

Similar Publications

Purpose: Looking while listening (LWL) tasks track eye movements while children view images (e.g., a dog and a ball) and hear an auditory prompt (e.

View Article and Find Full Text PDF

Parkinson's disease (PD) is a multifactorial disease caused by irreversible progressive loss of dopaminergic neurons (DANs). Recent studies have reported the successful conversion of astrocytes into DANs by repressing polypyrimidine tract binding protein 1 (PTBP1), which led to the rescue of motor symptoms in a chemically-induced mouse model of PD. However, follow-up studies have questioned the validity of this astrocyte-to-DAN conversion model.

View Article and Find Full Text PDF

Oligodendrocytes in Huntington's Disease: A Review of Oligodendrocyte Pathology and Current Cell Reprogramming Approaches for Oligodendrocyte Modelling of Huntington's Disease.

J Neurosci Res

December 2024

Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, School of Medical Science, Centre for Brain Research, University of Auckland, Auckland, New Zealand.

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder traditionally characterized by the selective loss of medium spiny neurons in the basal ganglia. However, it has become apparent that white matter injury and oligodendrocyte dysfunction precede the degeneration of medium spiny neurons, garnering interest as a key pathogenic mechanism of HD. Oligodendrocytes are glial cells found within the central nervous system involved in the production of myelin and the myelination of axons.

View Article and Find Full Text PDF

Aims: To investigate the effect of alcohol consumption on the clinical symptoms in a cohort of Progressive supranuclear palsy (PSP) patients.

Methods: We conducted a cross-sectional study focusing on possible and probable PSP patients in Qilu Hospital of Shandong University. Diagnoses and clinical phenotypes were confirmed using the 2017 Movement Disorder Society criteria and the Multiple Allocations eXtinction (MAX) rules.

View Article and Find Full Text PDF

Natural serine proteases and their applications in combating amyloid formation.

ADMET DMPK

November 2024

Medical Bionanotechnology, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Chettinad Health City, Kelambakkam, Chennai-603103, India.

Background And Purpose: Amyloidosis is a group of diseases including diabetes type II and neurological disorders, such as Alzheimer's disease, Parkinson's disease, prion disease, etc., where a common trait is observed; accumulation of misfolded protein at different parts of the body, especially the brain which manifests the typical symptoms like dementia, movement disorders, etc. These misfolded proteins, named amyloids, are protease resistant and thus it becomes difficult to manage these diseases in vivo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!